Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 10/2010

01.10.2010 | Original Article

Identification and characterization of Ch806 mimotopes

verfasst von: Lin Yang, Hua Jiang, Bizhi Shi, Huamao Wang, Jinjun Li, Hai Wang, Ming Yao, Zonghai Li

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 10/2010

Einloggen, um Zugang zu erhalten

Abstract

The chimeric antibody 806 (Ch806) is a promising antitumor agent that recognizes both the epidermal growth factor receptor variant III (EGFRvIII) and the overexpressed epidermal growth factor receptor (EGFR) in cancer tissues but does not recognize the wild type EGFR in normal tissues. However, passive antibody immunization could not produce effective antitumor titers unless the immunization was administered repeatedly over long periods. To overcome this limitation, we generated epitope mimics that bind to Ch806 and tested whether the peptide mimics could induce the production of similar antibodies when actively immunizing mice with the peptides. We used the PH.D-12 phage display peptide library to identify peptides that bind to the monoclonal antibody (mAb) 12H23, which also recognizes similar epitopes of Ch806. Two mimotopes (WHTEILKSYPHE and LPAFFVTNQTQD) were shown to mimic the mAb 12H23 and Ch806 epitope using immunoassays. The mimotopes were conjugated to immunogenic carrier proteins and used to intraperitoneally immunize BALB/c mice. Interestingly, sera from the mice immunized with the isolated mimotopes not only recognize the recombinant or synthetic 806 eptitope, but can also recognize EGFR that is overexpressed in A431 cells and EGFRvIII expressed in Huh7-EGFRvIII cells, whereas sera from mice immunized with the control peptide-KLH (keyhole limpet hemocyanin) and carrier KLH alone failed to show a similar reactivity. Furthermore, in an antibody-dependent cellular cytotoxicity assay (ADCC), the mimotope-induced antibodies specifically lysed human Huh-7-EGFRvIII cells. Our data indicate that the isolated mimotopes reported here may potentially be used as new alternative agents for treating cancer with EGFRvIII expression or EGFR overexpression.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Frederick L, Wang XY, Eley G, James CD (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60:1383–1387PubMed Frederick L, Wang XY, Eley G, James CD (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60:1383–1387PubMed
2.
Zurück zum Zitat Malden LT, Novak U, Kaye AH, Burgess AW (1988) Selective amplification of the cytoplasmic domain of the epidermal growth factor receptor gene in glioblastoma multiforme. Cancer Res 48:2711–2714PubMed Malden LT, Novak U, Kaye AH, Burgess AW (1988) Selective amplification of the cytoplasmic domain of the epidermal growth factor receptor gene in glioblastoma multiforme. Cancer Res 48:2711–2714PubMed
3.
Zurück zum Zitat Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, Vogelstein B (1992) Structural alterations of the epidermal growth-factor receptor gene in human gliomas. Proc Natl Acad Sci USA 89:2965–2969CrossRefPubMed Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, Vogelstein B (1992) Structural alterations of the epidermal growth-factor receptor gene in human gliomas. Proc Natl Acad Sci USA 89:2965–2969CrossRefPubMed
4.
Zurück zum Zitat Sugawa N, Ekstrand AJ, James CD, Collins VP (1990) Identical splicing of aberrant epidermal growth-factor receptor transcripts from amplified rearranged genes in human glioblas. Proc Natl Acad Sci USA 87:8602–8606CrossRefPubMed Sugawa N, Ekstrand AJ, James CD, Collins VP (1990) Identical splicing of aberrant epidermal growth-factor receptor transcripts from amplified rearranged genes in human glioblas. Proc Natl Acad Sci USA 87:8602–8606CrossRefPubMed
5.
Zurück zum Zitat Mendelsohn J (2002) Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20:1S–13SPubMed Mendelsohn J (2002) Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20:1S–13SPubMed
6.
Zurück zum Zitat Arteaga CL (2002) Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 29:3–9PubMed Arteaga CL (2002) Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 29:3–9PubMed
7.
8.
Zurück zum Zitat Nishikawa R, Ji XD, Harmon RC et al (1994) A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 91:7727–7731CrossRefPubMed Nishikawa R, Ji XD, Harmon RC et al (1994) A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 91:7727–7731CrossRefPubMed
9.
Zurück zum Zitat Olapade-Olaopa EO, Moscatello DK, MacKay EH, Horsburgh T, Sandhu DP, Terry TR, Wong AJ, Habib FK (2000) Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer 82:186–194CrossRefPubMed Olapade-Olaopa EO, Moscatello DK, MacKay EH, Horsburgh T, Sandhu DP, Terry TR, Wong AJ, Habib FK (2000) Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer 82:186–194CrossRefPubMed
10.
Zurück zum Zitat Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL, Wong AJ (1995) Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55:5536–5539PubMed Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL, Wong AJ (1995) Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55:5536–5539PubMed
11.
Zurück zum Zitat Cartenì G, Fiorentino R, Vecchione L, Chiurazzi B, Battista C (2007) Panitumumab a novel drug in cancer treatment. Ann Oncol 18:vi16–vi21CrossRefPubMed Cartenì G, Fiorentino R, Vecchione L, Chiurazzi B, Battista C (2007) Panitumumab a novel drug in cancer treatment. Ann Oncol 18:vi16–vi21CrossRefPubMed
12.
Zurück zum Zitat Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345CrossRefPubMed Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345CrossRefPubMed
13.
Zurück zum Zitat Zhang W, Gordon M, Lenz HJ (2006) Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies. Ann Med 38:545–551CrossRefPubMed Zhang W, Gordon M, Lenz HJ (2006) Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies. Ann Med 38:545–551CrossRefPubMed
14.
Zurück zum Zitat Luwor RB, Johns TG, Murone C, Su Huang H-J, Cavenee WK, Ritter G, Old LJ, Burgess AW, Scott AM (2001) Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2–7 or amplified epidermal growth factor receptor EGFR but not wild-type EGFR. Cancer Res 61:5355–5361PubMed Luwor RB, Johns TG, Murone C, Su Huang H-J, Cavenee WK, Ritter G, Old LJ, Burgess AW, Scott AM (2001) Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2–7 or amplified epidermal growth factor receptor EGFR but not wild-type EGFR. Cancer Res 61:5355–5361PubMed
15.
Zurück zum Zitat Scott AM, Lee F-T, Tebbutt N, Herbertson R, Gill SS, Liu Z et al (2007) A phase I clinical trial with monoclonal antibody Ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci USA 104:4071–4076CrossRefPubMed Scott AM, Lee F-T, Tebbutt N, Herbertson R, Gill SS, Liu Z et al (2007) A phase I clinical trial with monoclonal antibody Ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci USA 104:4071–4076CrossRefPubMed
16.
Zurück zum Zitat Rocha-Lima CM, Soares HP, Raez LE, Singal R (2007) EGFR targeting of solid tumors. Cancer Control 14:295–304PubMed Rocha-Lima CM, Soares HP, Raez LE, Singal R (2007) EGFR targeting of solid tumors. Cancer Control 14:295–304PubMed
17.
Zurück zum Zitat Johns TG, Adams TE, Cochran JR, Hall NE, Hoyne PA, Olsen MJ et al (2004) Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J Biol Chem 29:30375–30384CrossRef Johns TG, Adams TE, Cochran JR, Hall NE, Hoyne PA, Olsen MJ et al (2004) Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J Biol Chem 29:30375–30384CrossRef
18.
Zurück zum Zitat Riemer AB, Jensen-Jarolim E (2007) Mimotope vaccines: epitope mimics induce anti-cancer antibodies. Immunol Lett 113:1–5CrossRefPubMed Riemer AB, Jensen-Jarolim E (2007) Mimotope vaccines: epitope mimics induce anti-cancer antibodies. Immunol Lett 113:1–5CrossRefPubMed
19.
Zurück zum Zitat Adams TE (1990) Tolerance to self-antigens in transgenic mice. Mol Biol Med 7:341–357PubMed Adams TE (1990) Tolerance to self-antigens in transgenic mice. Mol Biol Med 7:341–357PubMed
20.
Zurück zum Zitat Felici F, Luzzago A, Folgori A, Cortese R (1993) Mimicking of discontinuous epitopes by phage-displayed peptides, II. Selection of clones recognized by a protective monoclonal antibody against the Bordetella pertussis toxin from phage peptide libraries. Gene 128:21–27CrossRefPubMed Felici F, Luzzago A, Folgori A, Cortese R (1993) Mimicking of discontinuous epitopes by phage-displayed peptides, II. Selection of clones recognized by a protective monoclonal antibody against the Bordetella pertussis toxin from phage peptide libraries. Gene 128:21–27CrossRefPubMed
21.
Zurück zum Zitat Luzzago A, Felici F, Tramontano A, Pessi A, Cortese R (1993) Mimicking of discontinuous epitopes by phage-displayed peptides, I. Epitope mapping of human H ferritin using a phage library of constrained peptides. Gene 128:51–57CrossRefPubMed Luzzago A, Felici F, Tramontano A, Pessi A, Cortese R (1993) Mimicking of discontinuous epitopes by phage-displayed peptides, I. Epitope mapping of human H ferritin using a phage library of constrained peptides. Gene 128:51–57CrossRefPubMed
22.
Zurück zum Zitat Cwirla SE, Peters EA, Barrett RW, Dower WJ (1990) Peptides on phage: a vast library of peptides for identifying ligands. Proc Natl Acad Sci USA 87:6378–6382CrossRefPubMed Cwirla SE, Peters EA, Barrett RW, Dower WJ (1990) Peptides on phage: a vast library of peptides for identifying ligands. Proc Natl Acad Sci USA 87:6378–6382CrossRefPubMed
23.
Zurück zum Zitat Wang H, Jiang H, Zhou M, Xu Z, Liu S, Shi B, Yao X, Yao M, Gu J, Li Z (2009) Epidermal growth factor receptor vIII enhances tumorigenicity and resistance to 5-fluorouracil in human hepatocellular carcinoma. Cancer Lett 279:30–38CrossRefPubMed Wang H, Jiang H, Zhou M, Xu Z, Liu S, Shi B, Yao X, Yao M, Gu J, Li Z (2009) Epidermal growth factor receptor vIII enhances tumorigenicity and resistance to 5-fluorouracil in human hepatocellular carcinoma. Cancer Lett 279:30–38CrossRefPubMed
24.
Zurück zum Zitat Parmley SF, Smith GP (1988) Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene 73:305–318CrossRefPubMed Parmley SF, Smith GP (1988) Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene 73:305–318CrossRefPubMed
25.
Zurück zum Zitat Panousis C, Rayzman VM, Johns TG, Renner C, Liu Z, Cartwright G, Lee F-T, Wang D, Gan H, Cao D, Kypridis A, Smyth FE, Brechbiel MW, Burgess AW, Old LJ, Scott AM (2005) Engineering and characterisation of chimeric monoclonal antibody 806 (Ch806) for targeted immunotherapy of tumours expressing de2–7 EGFR or amplified EGFR. Br J Cancer 92:1069–1077CrossRefPubMed Panousis C, Rayzman VM, Johns TG, Renner C, Liu Z, Cartwright G, Lee F-T, Wang D, Gan H, Cao D, Kypridis A, Smyth FE, Brechbiel MW, Burgess AW, Old LJ, Scott AM (2005) Engineering and characterisation of chimeric monoclonal antibody 806 (Ch806) for targeted immunotherapy of tumours expressing de2–7 EGFR or amplified EGFR. Br J Cancer 92:1069–1077CrossRefPubMed
26.
Zurück zum Zitat Sato N, Yabuki Y, Toh K, Ishii Y, Kikuchi K (1979) Separation of cell-dependent antibody (CDA) and inhibitory antibody by protein-A affinity chromatography and the effect of fractions on antibody-dependent cellular cytotoxicity (ADCC). Immunology 36:421–426PubMed Sato N, Yabuki Y, Toh K, Ishii Y, Kikuchi K (1979) Separation of cell-dependent antibody (CDA) and inhibitory antibody by protein-A affinity chromatography and the effect of fractions on antibody-dependent cellular cytotoxicity (ADCC). Immunology 36:421–426PubMed
27.
Zurück zum Zitat Wauben MH (2000) Immunological mechanisms involved in experimental peptide immunotherapy of T-cell-mediated diseases. Crit Rev Immunol 20:451–469PubMed Wauben MH (2000) Immunological mechanisms involved in experimental peptide immunotherapy of T-cell-mediated diseases. Crit Rev Immunol 20:451–469PubMed
28.
Zurück zum Zitat Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E (2005) Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J Natl Cancer Inst 97:1663–1670CrossRefPubMed Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E (2005) Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J Natl Cancer Inst 97:1663–1670CrossRefPubMed
Metadaten
Titel
Identification and characterization of Ch806 mimotopes
verfasst von
Lin Yang
Hua Jiang
Bizhi Shi
Huamao Wang
Jinjun Li
Hai Wang
Ming Yao
Zonghai Li
Publikationsdatum
01.10.2010
Verlag
Springer-Verlag
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 10/2010
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-010-0872-7

Weitere Artikel der Ausgabe 10/2010

Cancer Immunology, Immunotherapy 10/2010 Zur Ausgabe

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.